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Abstract Purpose: We set out to
evaluate alterations of the therapeutic
target genes KIT (CD 117), EGFR,
and HER-2 in human retinoblastoma.
Methods: Ninety-five formalin-fixed,
paraffin-embedded retinoblastomas
were brought into a tissue microarray
(TMA) format. Immunohistochemis-
try was performed to analyze the
expression of CD117, EGFR, and
HER-2. Fluorescence in situ hybrid-
ization (FISH) was utilized for de-
tection of EGFR amplifications.
Three tumors with strong CD117
positivity were sequenced for KIT
exon 11 mutations. Results: De-
tectable CD117 expression was seen
in 19% of all interpretable cases.
Sequence analysis of the three tumors
with the strongest CD117 expression
revealed no mutations. EGFR was
positive in 14% of all cases. No
EGFR amplification was observed by
FISH, however. All tumors were
negative for HER-2 expression.
Conclusions: Our data suggest that
selected cases of retinoblastoma may
be candidates for anti-EGFR and
imatinib mesylate (STI571) therapy.
Introduction
Retinoblastoma occurs in 1/20,000 newborns and is the
most common ocular malignancy that causes blindness in
children. Retinoblastoma is fatal if untreated, but over
95% of the patients survive if treated before the tumor
spreads outside the eye [38]. The primary goal of retino-
blastoma treatment is to save the patient’s life. At the same
time it is intended to save the eye and vision whenever
possible. Therefore, enucleation is performed only in ad-
vanced disease with no hope of preserving useful vision.
Other methods, such as external-beam radiotherapy, pla-
que radiotherapy, laser photocoagulation, cryotherapy, and
thermotherapy, are used with the intention of preserving
the eye in the case of small, organ-confined tumors [36].
In some instances, tumor reduction chemotherapy prior to
local treatment can be critical for avoiding enucleation or
external-beam radiotherapy [5, 37].
Once a tumor has spread through the sclera into the
orbit, systemic chemotherapy is the only treatment option
[11]. Carboplatin, vincristine, etoposide, and cyclophos-
phamide have been suggested as cytotoxic therapy regi-
mens but the success rate has been disappointing [8, 27,
40]. Recently, a new category of cytotoxic reagents have
been brought to market. These drugs specifically target
individual genes that are overexpressed or otherwise al-
tered in cancer cells. Trastuzumab (Herceptin), a hu-
manized antibody targeting the HER-2 gene, which is
overexpressed in about 20% of breast cancers, was the
first example of this new drug category. Trastuzumab has
been successfully used in a fraction of breast cancers [3,
7]. STI571 (Glivec), a small-molecule kinase inhibitor,
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weas initially developed to target the BCR-ABL fusion
gene product in chronic myeloid leukemia [10]. Subse-
quently this drug turned out also to inhibit KIT (CD117),
thus showing strong effects in patients with gastrointes-
tinal stroma tumors (GIST), a tumor entity known for a
particularly high level of KIT protein expression [24].
The epidermal growth factor receptor (EGFR) is another
receptor gene for which more than ten different anticancer
drugs have been developed [2, 4].
All these therapeutic target genes appear to be over-
expressed in various tumor types. It can therefore be an-
ticipated that the new drugs listed above will eventually
prove useful in many different tumor entities. In order to
collect information on their potential utility in retino-
blastoma, we analyzed a series of 95 retinoblastomas for
alterations of HER-2, CD117, and EGFR genes.
Material and methods
Tumors/tissue microarray construction
Formalin-fixed, paraffin-embedded tissue from 95 retinoblastomas
obtained in the years 1985–2001 was collected from the archives of
the institutes of ophthalmopathology and pathology, University of
Basel, Switzerland. The use of archival material was approved by
the local ethics commission. All cases were classified according to
the pTNM classification (UJCC 5th edn, 1997). The series included
29 males, 56 females, and nine patients of unknown sex. The mean
age was 3.33 years (range 0.25–24). The pT stage was pT1 in 1,
pT2 in 3, pT3 in 33, and pT4 in 58 cases.
Tissue microarray (TMA) construction was as previously de-
scribed [9]. In brief, tissue cylinders with a diameter of 0.6 mm
were punched from representative tumor areas of each “donor”
tissue block using a semi-automatic tissue arraying instrument and
brought into a recipient paraffin block. The TMA blocks were
constructed in two copies, each containing two to three samples of
the 95 retinoblastomas. Four-micrometer sections of the resulting
TMA blocks were transferred to an adhesive-coated slide system
(Instrumedics, Hackensack, NJ, USA) [(Fig. 1)].
Immunohistochemistry
The HercepTest (Dako, Glostrup, Denmark) was used for HER-2
protein analysis. Staining, control, and interpretation of the results
were carried out according to the manufacturer’s instructions.
The anti-CD117 antibody from Dako (A4502) was used for
CD117 analysis. In a comparison of multiple antibodies, A4502 had
yielded the highest specificity, the strongest specific staining, and
the least background (Philip Went, personal communication).
A4502 was applied at a dilution of 1:300 at room temperature for
2.5 h, after 3 min pressure cooking in 10 mM sodium citrate buffer
(pH 6.0) for antigen retrieval. Endogenous peroxidase was blocked
using 0.3% hydrogen peroxidase diluted in methanol for 30 min. A
standard ABC technique (Vector ABC kit) using DAB for visual-
ization was used. For specificity control, a preabsorption of the
antibody was performed (CD117 peptide stock solution, Neo-
markers PP1518). This antigen matches the sequence of the epitope
recognized by the polyclonal antibody of Dako. A case of GIST
was used as a positive control (Fig. 2).
The monoclonal antibody EGFR (1:50; Triton Biosciences,
Alameda, CA, USA) was used for EGFR analysis. The optimal titer
for EGFR was defined as the dilution that gave clearly identifiable
membrane staining and negligible background on human placental
samples. The optimal protocol used an antibody dilution of 1:50,
antigen retrieval and an avidin-biotin complex immunoperoxidase
procedure (ABC Elite, Vector, Burlingame, CA, USA) for visual-
ization of antibody binding. Human placenta and a slide where the
primary antibody was omitted served as positive and negative
controls.
The proportion of cells positive for CD117 and EGFR was es-
timated and the staining intensity was semi-quantitatively recorded
as 1+, 2+, or 3+. Only membranous staining was considered. For
statistical analysis, the staining results were categorized into four
groups. Tumors without any staining were considered negative.
Tumors with 1+ staining intensity in <60% of cells and 2+ intensity
in <30% of cells were considered weakly positive. Tumors with 1+
staining intensity in 60%, 2+ intensity in 30% x>80%, or 3+
intensity in <30% of cells were considered moderately positive.
Tumors with 2+ intensity in 80% or 3+ intensity in 30% of cells
were considered strongly positive.
Fig. 1 Retinoblastoma tissue microarray (TMA): overview of an
H&E-stained TMA section
Fig. 2 Gastrointestinal stromal tumor served as a positive control
(40-fold magnification)
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Sequence analysis for CD117
Three retinoblastomas showing intense CD117 staining were se-
lected for KIT mutation analysis. Deparaffinizing of the formalin-
fixed tissues and DNA extraction was performed according to
protocols of Qiagen (Qiagen, Basel, Switzerland). Exon 11 was
amplified using a semi-nested PCR approach, and was sequenced
directly using Big Dye Terminators Cycle Sequencing Ready Re-
action Kit (Applied Biosystems, Foster City, CA, USA). Sequence
products were analyzed on an ABI Prism 310 Genetic Analyzer
(Applied Biosystems).
Statistical analysis
Chi-square statistic was used for comparisons of gene alteration
frequencies between tumors of different stages or grades.
Results
CD117
Immunostaining could be evaluated in 73 of the 95 cases
(77%). Analysis failures were due to either lack of tissue
on the TMA section or lack of vital tumor cells in the
arrayed samples. Positive CD117 staining was seen in 14
of 73 interpretable tumors (19.2%) (Fig. 3). The staining
was membranous in all cases. Positivity was weak in
four, moderate in seven, and strong in three cases. There
were no differences in frequency or intensity of KIT
staining between tumors of different stages or grades.
Sequencing of exon 11 did not reveal KIT mutations in
the three tumors with strong immunohistochemical KIT
positivity.
EGFR
Immunostaining could be evaluated in 80 of 95 cases
(84%). Positive staining was seen in 11 of 80 inter-
pretable tumors (14%). The staining was membranous in
all cases (Fig. 4). Positivity was weak in two, moderate in
two, and strong in seven cases. The FISH analysis
yielded interpretable data in 50% of tumors. None of
them showed gene amplification according to our defi-
nition (Fig. 5).
Fig. 3 Example of three tumors positive for CD-117 (KIT). a Weak positivity; b moderate positivity; c strong positivity; d example of a
tumor negative for CD-117 (KIT) (100-fold magnification)
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HER-2
Immunostaining could be evaluated in 80 of 95 cases
(84.2%). None of the tumors showed positive HER-2
staining (Fig. 6). For this reason, no HER-2 FISH analysis
was attempted.
Discussion
A TMA was used to evaluate gene alterations in a series
of 95 retinoblastomas. In this method, a number of minute
tissue samples (diameter 0.6 mm) are analyzed on one
microscope glass slide. It is evident that focal gene al-
terations are not always detected in a TMA setting.
However, this perceived disadvantage seems to be com-
pensated by the high number of tumors that can be in-
cluded in a TMA study and maximal standardization of
the analyses [16, 32, 33]. In fact, all tissue samples on one
TMA section are processed under absolutely identical
conditions. Numerous studies have shown that represen-
tative information can be obtained in TMA analyses [9,
26]. For example, the known frequencies of amplifica-
Fig. 4 Examples of EGFR-positive tumors. a Weak positivity; b moderate positivity; c strong positivity; d example of a tumor negative
for EGFR (40-fold magnification)
Fig. 5 Example of an EGFR-positive tumor: FISH analysis showed
no gene amplification (100-fold magnification)
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Fig. 6 A tumor negative for HER-2 (40-fold magnification)
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